NF2

NF2 (Neurofibromin 2) is a gene that produces a protein called merlin, which acts as a tumor suppressor, meaning it helps keep cells from growing out of control. When the NF2 gene is damaged or lost, cells can divide unchecked, contributing to the development of certain cancers including mesothelioma. NF2 mutations are among the most common genetic changes found in mesothelioma tumors.

Origin

The NF2 gene was identified in 1993 by researchers studying neurofibromatosis type 2, an inherited disorder that causes nervous-system tumors. The gene's protein product was named "merlin" (moesin-ezrin-radixin-like protein) because of its structural similarity to a family of cell-membrane proteins.

Significance in Asbestos Context

NF2 mutations or deletions are found in roughly 40-50% of pleural mesotheliomas, making it one of the signature genetic alterations of this disease. When pathologists or oncologists analyze tumor tissue, they may report NF2 loss alongside other changes like BAP1 or CDKN2A loss. Together these form a molecular fingerprint that supports a mesothelioma diagnosis and can distinguish it from look-alike cancers. The NF2 mutations seen in asbestos-related mesothelioma are almost always somatic (acquired in the tumor cell from environmental damage), not inherited, which is important medically and legally: the genetic finding does not mean the cancer was "genetic" rather than caused by asbestos. Researchers continue to study NF2-targeted therapies, so a confirmed NF2 alteration may also affect eligibility for certain clinical trials.

Example Sentence

The pathology report noted loss of NF2 and BAP1 in the tumor tissue, a molecular profile consistent with asbestos-induced pleural mesothelioma.

Related Terms

BAP1, CDKN2A, Tumor Suppressor Gene, Somatic Mutation, Merlin, Mesothelioma

Notes

• Ask your oncologist or pathologist whether molecular or next-generation sequencing (NGS) testing was done on your tumor and whether NF2, BAP1, and CDKN2A status are reported. These results may guide treatment and clinical trial eligibility.
• Request a copy of any molecular pathology or genomic testing report (often from companies like Foundation Medicine, Caris, or Tempus) and keep it with your medical records; these documents can support diagnostic certainty in a legal claim.
• If NF2 loss is reported, ask whether you qualify for clinical trials involving FAK inhibitors or other merlin-pathway therapies that have been studied in mesothelioma.
• Clarify with your medical team that somatic NF2 changes in your tumor are not the same as inherited neurofibromatosis type 2 and do not mean your family members are at increased risk.